General health
General health
Once-daily basal Insulin Glargine versus thrice-daily Prandial Insulin Lispro in people with type 2 diabetes on oral hypoglycemic agents
2008-04-02
As type 2 diabetes mellitus progresses, oral hypoglycemic agents often fail to maintain blood glucose control and insulin is needed. Authors investigated whether the addition of once-daily insulin glargine is non-inferior to three-times daily prandial insulin lispro in overall glycemic control in adults with inadequately controlled type 2 diabetes mellitus taking oral hypoglycemic agents.
استخدام الأدوية المثبطة لمستقبلات البيتا (beta blocker) وارتباطها بنسبة تقليل وفيات مرضى المستشفيات المصابين بداء الانسداد الرئوي المزمن
2008-04-02
تعتبر أمراض القلب والأوعية الدموية هي السبب الرئيسي للوفيات للمرضى المصابين بمرض الانسداد الرئوي المزمن ( COPD ) وللمرضى المتوقع استشفاؤُهم (دخولهم للمستشفى) بسبب التفاقم الطبي لحالاتهم المرضية الحادة ، سواء كانت حالات الوفاة في المستشفى أو بعد الخروج منه.
Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
2008-04-09
No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.
The objectives of the study were to compare the effects of an insulin sensitizer, Pioglitazone, with an insulin secretagogue, Glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes.
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease
2008-04-09
Mild and moderate chronic kidney disease (CKD) is associated with decreased survival and increased adverse events after a percutaneous coronary intervention (PCI). Therapy with Clopidogrel decreases adverse events in large patient populations. Therefore, authors sought to determine the efficacy and safety of long-term Clopidogrel therapy in patients with CKD.
Recent Study Indicates A Higher Risk of Heart Attack In Patients Infected With HIV-1 Taking Ziagen (Abacavir) and Videx (Didanosine)
2008-04-09
The U.S Food and Drug Administration (FDA), the equivalent of the Saudi Food and Drug Authority (SFDA), issued an Early Communication about recent findings of The Data Collection on Adverse Events of Anti-HIV Drugs Study. Data analyses from this study indicate a higher risk of heart attack in patients infected with HIV-1 who were taking Ziagen (abacavir) or Videx (didanosine) as part of their drug therapy. Ziagen 300 mg is registered in Saudi Arabia and is indicated for HIV infections .
An Update in the Prescribing Information of Zanamivir (Relenza)
2011-12-18
The U.S. Food and Drug Administration (FDA), the American counterpart to the Saudi Food and Drug Authority (SFDA), together with GlaxoSmithKline informed healthcare professionals of changes to the WARNINGS AND PRECAUTIONS sections of prescribing information for Zanamivir, marketed as Relenza.
Zanamivir was approved in Saudi Arabia in 2004 for the treatment and prophylaxis of influenza virus. It is an inhibitor of influenza virus neuraminidase affecting release of viral particles.
An Update in the Prescribing Information of Exubera
2008-04-15
The U.S. Food and Drug Administration (FDA), the American counterpart to the Saudi Food and Drug Authority (SFDA), together with Pfizer informed healthcare professionals and patients of updated safety information in the WARNINGS section of prescribing information for Exubera, a short-acting insulin you breathe in through your mouth using the Exubera inhaler that helps to control high blood sugar in adults with diabetes.
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
2008-04-16
In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. Authors compared the ACE inhibitor Ramipril, the ARB Telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.
Effects of darbepoetin α on ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
2008-04-23
Anemia is a frequent condition in chronic heart failure (CHF) that affects adversely long-term cardiac outcomes. Authors sought to investigate the effects of recombinant human erythropoietin analogue darbepoetin α on left (LV) and right ventricular (RV) function and neurohormonal activation in patients with CHF and anemia.
A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension
2008-04-29
The objective of this study was to evaluate the effects of losartan ± hydrochlorothiazide (HCTZ) versus placebo in obese patients with systolic and diastolic hypertension.
Randomized patients (n = 261) were non-diabetic with systolic blood pressure (SBP) ≥ 140 and ≤ 180 mmHg and diastolic BP (DBP) ≥ 95 and ≤ 115 mmHg, body mass index > 30 kg/m2, and waist circumference > 40 (males)/> 35 (females) inches.